ICB&DD Member's Research Highlights
2019-2020 Basic Research Highlights
Boros, A. B. Packard. “Radioactive transition metals for imaging and therapy” Chem Rev.119, 870–901 (2019).
Yue, L. Li, S. C. McGuire, N. Hurley, S. S. Wong, “Quantum Dot-Sensitized 1D-based Heterostructures for Optical-related Applications”, Energy Environ. Sci., 12(5), 1454-1494 (2019).
Kyriazis ID, Hoffman M, Gaignebet L, Lucchese AM, Markopoulou E, Palioura D, Wang C, Bannister TD, Christofidou-Solomidou M, Oka SI, Sadoshima J, Koch WJ, Goldberg IJ, Yang VW, Bialkowska AB, Kararigas G, Drosatos K. KLF5 Is Induced by FOXO1 and Causes Oxidative Stress and Diabetic Cardiomyopathy. Circ. Res. 2021 Feb 5;128(3):335-357. doi: 10.1161/CIRCRESAHA.120.316738. Epub 2020 Dec 2. PMID: 33539225
Lee, J. W.; Lim, S.; Maienshein, D. N.; Liu, P.; Ngai, M.-Y. “Redox-Neutral TEMPO Catalysis Toward Direct Radical (Hetero)Aryl C-H Di- and Trifluoromethoxylation” Angew. Chem. Int. Ed. 2020, 59, 21475.
C. Marker, A. P. King, R. V. Swanda, B. A. Vaughn, E. Boros, S. B. Qian, J. J. Wilson. “Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes”Angew. Chem. Int. Ed.59, 13391-13400 (2020)
Khayyo VI, Hoffman RM, Wang H, Bell JA, Burke JE, Reue K, Airola MV. Crystal structure of a lipin/Pah phosphatidic acid phosphatase. Nat. Commun. 2020, 11(1):1309
Rageul J, Park JJ, Zeng PP, Lee EA, Yang J, Hwang S, Lo N, Weinheimer AS, Schärer OD, Yeo JE, Kim H. SDE2 integrates into the TIMELESS-TIPIN complex to protect stalled replication forks. Nat Commun.2020 Oct 30;11(1):5495. doi: 10.1038/s41467-020-19162-5. PMID: 33127907; PMCID: PMC7603486.
Oni TE, Biffi G, Baker LA, Hao Y, Tonelli C, Somerville TDD, Deschênes A, Belleau P, Hwang CI, SánchezRivera FJ, Cox H, Brosnan E, Doshi A, Lumia RP, Khaledi K, Park Y, Trotman LC, Lowe SW, Krasnitz A, Vakoc CR, Tuveson DA. “SOAT1 promotes mevalonate pathway dependency in pancreatic cancer”. J Exp Med. 2020 Sep 7;217(9):e20192389. doi: 10.1084/jem.20192389. PMID: 32633781.
Bowling FZ, Salazar CM, Bell JA, Huq TS, Frohman MA, Airola MV. “Crystal structure of human PLD1 provides insight into activation by PI(4,5)P2 and RhoA”. Nat Chem Biol. 2020 Apr;16(4):400-407. doi: 10.1038/s41589-020-0499-8. Epub 2020 Mar 16. PMID: 32198492
Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA. “Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death”. Clin Cancer Res. 2019 Dec 1;25(23):7162-7174. doi: 10.1158/1078-0432.CCR-19-0302. Epub 2019 Sep 16. PMID: 31527169
Zhiqiang Yan, Jin Wang, “Funneled energy Landscape unifies principles of protein binding and evolution”. Proc. Natl. Acad. Sci. U.S.A. 117 (44), 27218-27223 (2020).
Nowak DG, Katsenelson KC, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MM, Casanova-Salas I, Jibilian MC, Buckholtz CL, Ambrico AJ, Pan CH, Wilkinson JE, Newton AC, Trotman LC. “The PHLPP2 phosphatase is a druggable driver of prostate cancer progression”. J Cell Biol. 2019 Jun 3;218(6):1943-1957. doi: 10.1083/jcb.201902048. Epub 2019 May 15. PMID: 31092557
A. Vaughn, S. H. Ahn, E. Aluicio-Sarduy, J. Devaraj, A. P Olson, J. W. Engle and E. Boros. “Chelation with a Twist: A Bifunctional Chelator to Enable Room Temperature Radiolabeling and Targeted PET Imaging with Scandium-44”Chem. Sci.11, 333 – 342 (2020)
Rong, C. Wang, X. Zhang, Y. Wei, M. Zhang, D. Liu, H. Farhan, S. Abdul Momen Ali, Y. Liu, A. Taouil, W. Guo, Y. Wang, I. Ojima, S. Yang, H. Wang, “A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells”, Cancer Lett. 491, 36-49 (2020). DOI: 10.1016/j.canlet.2020.06.025. PMID: 32730778
Hanson SM, Georghiou G, Thakur MK, Miller WT, Rest JS, Chodera JD, Seeliger MA. “What Makes a Kinase Promiscuous for Inhibitors?”Cell Chem Biol. 2019 Mar 21;26(3):390-399.e5. doi: 10.1016/j.chembiol.2018.11.005. Epub 2019 Jan 3.PMID: 30612951
Haranahalli, K., Lazzarini, C., Sun, Y., Zambito, J., Pathiranage, S., McCarthy, J. B., Mallamo, J. P., Del Poeta, M., Ojima, I. “SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents”, J. Med. Chem. 62(17), 8249-8273 (2019) doi: 10.1021/acs.jmedchem.9b01004. PMC6755904
Pandey, C. Savino, S. H. Ahn, Z. Yang, S. G. Van Lanen, E. Boros. “Theranostic Gallium Siderophore Ciprofloxacin Conjugate with Broad Spectrum Antibiotic Potency”J. Med. Chem.62, 9947-9960 (2019).
Krishnan H, Miller WT, Blanco FJ, Goldberg GS. “Src and podoplanin forge a path to destruction”
Drug Discov Today 2019 Jan;24(1):241-249. doi: 10.1016/j.drudis.2018.07.009. Epub 2018 Aug 2.PMID: 30077780
Werneburg GT, Nguyen A, Henderson NS, Rackley R, Shoskes DA, Le Seur AL, Corcoran AT, Katz AE, Kim J, Rohan AJ, Thanassi DG: “The natural history and composition of urinary catheter biofilms: early uropathogen colonization with intraluminal and distal predominance”. J Urol 2020 Feb;203(2):357-364.doi: 10.1097/JU.0000000000000492. Epub 2019 Aug 20.
Gaudino SJ, Beaupre M, Lin X, Joshi P, Rathi S, McLaughlin PA, Kempen C, Mehta N, Eskiocak O, Yueh B, Blumberg RS, van der Velden AWM, Shroyer KR, Bialkowska AB, Beyaz S, Kumar P. “IL-22 receptor signaling in Paneth cells is critical for their maturation, microbiota colonization, Th17-related immune responses, and anti-Salmonella immunity” Mucosal Immunol. 2020 Oct 15. doi: 10.1038/s41385-020-00348-5. PMID: 33060802
Kim CK, Saxena M, Maharjan K, Song JJ, Shroyer KR, Bialkowska AB, Shivdasani RA, Yang VW. “Krüppel-like factor 5 regulates stemness, lineage specification, and regeneration of intestinal epithelial stem cells” Cell Mol Gastroenterol Hepatol. 2020;9(4):587-609. doi: 10.1016/j.jcmgh.2019.11.009. PMID: 31778829
Youn, G., Cervin, J., Yu, X., Bhatia,S. R., Yrlid, U. and Sampson, N. S. “Targeting multiple binding sites on cholera toxin B with glycomimetic polymers promotes formation of protein–polymer aggregates,” 2020, 21, 4878-4887, Biomacromolecules. DOI: 10.1021/acs.biomac.0c01122 PMC7755116
Psonis JJ, Thanassi DG: “Therapeutic approaches targeting the assembly and function of chaperone-usher pili”. EcoSal Plus 2019 Mar;8(2):10.1128/ecosalplus.ESP-0033-2018.doi: 10.1128/ecosalplus.ESP-0033-2018.
Soung YH, Chung H, Yan C, Fesler A, Kim H, Oh ES, Ju J, Chung J. “Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers”Cancers2020 Aug 7;12(8). doi: 10.3390/cancers12082209. PMID: 32784600; PMCID: PMC7463492.
C.-H. Pan, Y. Otsuka, B. Sridharan, M. Woo, S. Babu, C.V. Leiton, J. D. K. Bai, D. K. Chang, A. Biankin, L. Scampavia, T. Spicer, L. F. Escobar-Hoyos, K.R. Shroyer. “An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer”. Mol Oncol. 2020 1800-1816. PMID: 32533886
Boadi, F. O., Zhang, J., Yu,X., Bhatia,S. R., and Sampson, N. S. “Alternating ring-opening metathesis polymerization provides easy access to functional and fully degradable polymers,” 2020, 53, 5857-5868 Macromolecules. DOI: 10.1021/acs.macromol.0c01051
Wang, X. Wang, Y. Sun, S. Yan, G. I. Botchkina, I. Ojima, “Design, Synthesis and SAR study of 3rd-generation taxoids bearing 3-CH3, 3-CF3O and 3-CHF2O groups at the C2-benzoate position”, Bioorg. Chem. 95, 103523 (2020). PMID: 31911305; PMC7561017
Iuliano, J. N.; Collado, J. T.; Gil, A. A.; Ravindran, P. T.; Lukacs, A.; Shin, S.; Woroniecka, H. A.; Adamczyk, K.; Aramini, J. M.; Edupuganti, U. R.; Hall, C. R.; Greetham, G. M.; Sazanovich, I. V.; Clark, I. P.; Daryaee, T.; Toettcher, J. E.; French, J. B.; Gardner, K. H.; Simmerling, C. L.; Meech, S. R.; Tonge, P. J. “Unraveling the Mechanism of a LOV Domain Optogenetic Sensor: A Glutamine Lever Induces Unfolding of the Jalpha Helix”, ACS Chem Biol, 2020, 15, 2752-2765. DOI: 10.1021/acschembio.0c00543
Li, Y.; Daryaee, F.; Yoon, G. E.; Noh, D.; Smith-Jones, P. M.; Si, Y.; Walker, S. G.; Turkman, N.; Meimetis, L.; Tonge, P. J. “Positron Emission Tomography Imaging of Staphylococcus aureus Infection Using a Nitro-Prodrug Analogue of 2-[(18)F]F-p-Aminobenzoic Acid”, ACS Infect Dis, 2020, 6, 2249-2259. DOI: 10.1021/acsinfecdis.0c00374
Bai L, Parkin LA, Hong Z, Shum R, Previti ML, Seeliger, JC. (2020) Dimethylaminophenyl Hydrazides as Inhibitors of the Lipid Transport Protein LprG in Mycobacteria. ACS infect Dis. 2020, 6, 4, 637–648,https://doi.org/10.1021/acsinfecdis.9b00497
Knatko, E. V.; Tatham, M.; Zhang, Y.; Castro, H. C.; Higgins, M.; Naidu, S. D.; Leonardi, C.; De la Vega, L.; Honda, T.; Griffin, J. L.; Hay, R. T.; Dinkova-Kostova, A. T. Downregulation of Keap1 confers features of a fasted metabolic state. iScience 2020, 23, 101638; doi.org/10.1016/j.isci.2020.101638
Roa-Peña, C.V. Leiton, S Babu, E.A. Vanner, C.-H. Pan, A. Akalin, J. Bandovic, R.A. Moffitt, L.F. Escobar-Hoyos, K.R. Shroyer. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci. Rep. 2019 Aug 2;9(1):11239.doi: 10.1038/s41598-019-47519-4. PMID: 31375762
Carbonetti, C. Converso, T. Clement, C. Wang, L. Trotman, I. Ojima, M. Kaczocha, “Docetaxel/ cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth”, TheProstate 80(1), 88-98 (2020), DOI:10.1002/pros.23921. PMC7063589
Zhou,M. W. Elmes, J. M. Sweeney, O. M. Joseph, J. Che, H.-C. Hsu, H. Li, D. G. Deutsch, I. Ojima, M. Kaczocha, R. C. Rizzo, “Identification of Fatty Acid Binding Protein 5 Inhibitors Through Similarity-based Screening”, Biochemistry 58(42), 4304-4316 (2019): doi: 10.1021/acs.biochem.9b00625. PMC6812325
2018 Highlights
Spin-off companies
Chronus Pharmaceuticals, Inc.
The Chronus Pharm. (Dr. Nicole Sampson, President) acquired a Phase 1 NIH/STTR grant
for pediatric TB diagnostic feasibility work. LI BioHub REACH Proof of Concept grant
was acquired, as well. Also, the Chronus Pharm. was selected as a StartupNY company
by the NYS Governor’s Office. The CEO (Dr. Labros Meimetis) has been appointed.
MicroRid Technologies, Inc.
Dr. Maurizio Del Poeta founded “MicroRid Technologies Inc.” together with Brian McCarthy
(CEO) and John Mallamo (CRO). The company is developing a new class of antifungal
agents targeting the synthesis of fungal glucosylceramide with ICB&DD’s Discovery
Chemistry
Lab. It is also currently developing a new ceramide synthase assay for the screening
and identification of a specific fungal ceramide synthase inhibitor(s).
CuraMir Therapetuic, Inc.
CuraMir Therapeutic, Inc. was established in 2018 founded by Dr. Jingfang Ju. The mission
of the company is to develop novel miRNA based cancer therapeutics to improve qualify
and extend patient life. The company has licensed several miRNA platform
technologies from Stony Brook University.
Targagenix Inc.
As reported previously, Targagenix (CEO: James Eagan, Ph.D., MBA from SBU) licensed
PUFA-Taxoid anticancer drug conjugates (Inventor: Dr. Ojima) from the Research Foundation
of SUNY to develop these drug candidates. An NCI Contract was granted for the development
of NE-PUFA-taxoids (nanoemulsion formulation of PUFAtaxoid conjugates) (Targagenix-SBU-Northeastern
Univ. consortium). The project has been moving well and pre-IND feedback from FDA
was encouraging and informative. Grant applications and VC fund acquisition have been
actively ongoing.
Drug Discovery and Development
Dr. Nicole Sampson is developing azasteroids for treatment of tuberculosis. Cholesterol metabolism is
important for persistence of Mycobacterium tuberculosis (Mtb) in mouse models of infection.
Dr. Sampson’s group identified lead compounds that show excellent
antibacterial activity against M. tb. The inhibitor scaffold has high host in vivo
stability, low host toxicity, and excellent host bioavailability. A lead compound
has good bioavailability and is accumulated in the mouse lung, as well as shows no
sign of
potential drug-drug interaction by in vitro tests. She assumed the President of Chronus Pharmaceuticals,
Inc. Dr. Nicole Sampson is also developing a method for early detection of TB. The diagnosis rate of childhood
TB is very low due to the lack of accurate diagnostic methods for children who cannot
produce sputum samples. Her group identified a modified serum lipoprotein (MtLDL)
that results from exposure to Mycobacterium tuberculosis, and have established an
ELISA assay using anti-MtLDL mAbs that are being developed as a minimally invasive,
robust, serum-based diagnostic tool to detect active tuberculosis. She obtained NIH
REACH grant, as well as an STTR grant through Chronus Pharm. CPI-613, a novel “altered
energy metabolism directed (AEMD)” anticancer drug invented
by Dr. Bingham, which was licensed to and being developed by the Cornerstone Pharmaceuticals,
has reached Phase II human clinical trials for AML, MDS and solid tumors. Also, it
is in Phase I and I/II for several indications and combinations, including
FOLFIRINOX (folic acid + 5-FU).
Development of NE-DHA-SBT-1214 by TargaGenix, Inc. (Dr. James Egan), based on Dr. Iwao Ojima’s invention of DHA-taxoids in combination with the unique nanoemulsion technology developed
by Dr. Amiji (Northeastern Univ.), against CSC-initiated tumor xenografts are moving
well. IND filing is in sight. Combination with anti-PDL-1 antibody exhibited a synergistic
effect on highly challenging pancreatic cancer (PDAC) in vivo.
Dr. Jarrod French’s laboratory is developing novel Sts-1 inhibitors for deadly pathogen infections through
structure-based drug discovery approach. This project/invention has secured a drug
discovery grant from DOD, Fusion award from SOM and REACH grant
from NIH.
Dr. Kenneth Shroyer and Dr. Luisa Escobar-Hoyos discovered that keratin 17 (K17) protein and mRNA serve as excellent prognostic biomarkers
for patient survival, independent of tumor grade and stage in triple-negative breast,
cervical and pancreatic cancers. They also defined
binding domains that mediate K17 interaction with p27 and made K17 as druggable target.
This team received the 2018 Pancreatic Cancer Action Network (PanCAN) Translational
Research Award to further promote this project.
Dr. Jingfang Ju’s invention on novel miR-129 derivatives, bearing 5-FU in place of U units in the sequence
show early promise as totally new approach to gene-based chemotherapy. A US Patent
application was filed. Three more NTDs have been filed, which will lead to
patent applications. To pursue miRNA-based cancer therapeutics development, CuraMir Therapeutics,
Inc. was founded.
Baldoxolone methyl (BARD), invented by Dr. Tadashi Honda, is undergoing two Phase III studies: (i) for connective tissue disease-associated
pulmonary arterial hypertension (CTD-PAH) by Reata Pharmaceuticals, Inc. and (ii)
for diabetic nephropathy by Kyowa Hakko Kirin.
Both cases showed excellent Phase II and Phase IIb results. Reata is currently conducting
a global Phase 3 clinical study on BARD in connective tissue disease associated PAH
and a global Phase II/III clinical study in Alport syndrome.
A tricyclic cyanoenone, TBE-31, invented by Dr. Tadashi Honda, is an another Nrf2 activator, and has various features that BARD does not have.
His team found that TBE-31 reverses high-fat diet and fructose-induced nonalcoholic
steatohepatitis (NASH) in an Nrf2-
dependent manner. Since currently there are no treatments for NASH other than lifestyle changes,
their findings offer hope to patients with NASH.
Dr. Maurizio Del Poeta’s laboratory has identified fungal ceramide synthase as novel drug target, and found
a few hit compounds through HTP screening. Then he started collaboration with Dr. Iwao Ojima and ICB&DD’s Drug Discovery Lab. for hit-to-lead optimization. A large
size NIAID grant has been secured and three patent applications were filed and two
WO patent applications were published. These compounds will be licensed to MicroRid
Inc.
Development of novel fatty acid binding protein (FABP) inhibitors as new type of analgesic
and anti-inflammatory agents, based on the lead compound, SB-FI-26, is moving well,
a new PCT patent application for optimized compounds, exhibiting higher potency as
well as sub-type selectivity, was filed. The FABP targets and FABP inhibitors were
licensed to the Artelo Biosciences and preclinical drug development has been actively
ongoing.
Dr. Peter Tonge developed [18F]F-PABA, a fluorine-18 analog of p-aminobenzoic acid. [18F]FPABA is
able to defect and quantify bacterial infection in a soft tissue model of S. aureus
infection using PET imaging. A Phase 1 STTR grant to evaluate [18F]F-PABA in a preclinical
model of prosthetic joint infection was obtained through Chronus Pharm.
Dr. Lori Chan identified Skp2 E3 ligase as excellent drug target in castration-resistant prostate
cancer and a hit compound was identified by HTP assay. A collaboration with Dr. Jin Wang and Dr. Iwao Ojima for hit-to-lead optimization has led to the identification
of highly potent lead compounds, which will be further optimized.
Dr. Jarrod French’s laboratory is developing novel Sts-1 inhibitors for deadly pathogen infections through
structure-based drug discovery approach. This project/invention has secured a drug
discovery grant from DOD, Fusion award from SOM and REACH grant
from NIH. In addition, he received an NIH R21 grant on this drug discovery project.
Biomarkers and Targets
Keratin 17 was discovered in Dr. Kenneth Shroyer’s laboratory as diagnostic and prognostic biomarkers for cervical intraepithelial neoplasia
(CIN) and squamous-cell carcinoma (SCC). Now, Keratin 17 was also validated as a highly
sensitive and specific biomarker
for prognosis of pancreatic cancer. Two US Patent applications were filed and published (US20160187341A1,
US20180340935A1). In addition, MR spectroscopy models were developed to evaluate metabolic
properties impacted by keratin 17 in mouse xenograft
models of pancreatic cancer.
The miRNAs, miR192 and miR215, identified in Dr. Jingfang Ju’s laboratory, would serve as new biomarkers in cancer diagnosis and prognosis in colorectal, gastric and endometrial cancers. These miRNAs would also provide excellent targets for novel anti-cancer therapeutics.
RNF8 E3 ligase was discovered by Dr. C.-H. Chan as a novel cancer stem cell (CSC)/EMT activator and drug target. Dr. Chan also discovered Skp2 E3 ligase as excellent drug target in castration-resistant prostate cancer.
Fatty acid binding proteins (FABPs) discovered by Dr. Dale Deutsch’s laboratory are excellent targets for anti-inflammatory and analgesic drug discovery.
It has been shown by ICB&DD Team (Deutsch, Kaczocha, Ojima, Rizzo and Li) that the inhibition of FABPs
increases the anandamide level, leading to potent anti-nociceptive effects. In addition, the
inhibition of FABP5 and FABP7 have been shown to lead to tumor suppression, and thus
FABP inhibitors can be developed for cancer therapy, as well.
FadA5, a flavin adenine dinucleotide and a thiolate from M. tuberculosis was identified
by Dr. Nicole Sampson to be a new target for anti-TB drug discovery. Structural comparisons to human thiolases
revealed that it should be possible to target FadA5 specifically and the
steroid-bound structure provides a solid basis for the development of inhibitors against FadA5.
Dr. Jian Cao has found that the hemopexin domains of MMP9 and 14 are key functional components of these MMPs, which are required for cancer cell migration and invasion. Thus, these hemopexin domains would provide excellent targets for cancer chemotherapeutics to block cancer metastasis.
The V777L and other activated mutant forms of ErbB2 were identified by Dr. Todd Miller as potential target for drug discovery for breast cancer chemotherapy.
Biliverdin reductase B (BLVRB) is considered an excellent target for the development of drugs for oxidative stress-mediated diseases. Dr. Wadie Bahou and Dr. Jin Wang are screening inhibitors of BLVRB.
Cancer initiating cells (CICs), obtained by isolation from clinical samples and cultivation (Dr. Galina Botchkina, colon and prostate cancers), have been successfully used to produce tumor xenografts
in nod-scid mice. These tumor xenografts are essential for drug
discovery targeting CICs.
Phosphoinositide 3-kinase (PI3K) isoform, p100, identified in Dr. Richard Lin’s laboratory, is a potential target for a novel therapy for the treatment of pancreatic cancer, either by targeted therapy or in combination with standard chemotherapy.
Serine hydrolases in the mycobacterial cell wall were identified in Dr. Jessica Seeliger’s laboratory as novel targets for possible intervention of TB by small-molecule inhibitors.
Basic Research Highlights
He P, Yang JW, Yang VW, Bialkowska AB. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation,
Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth
in Mice. Gastroenterology,
2018,154(5):1494-1508.e13
Abedini A., Cao P., Plesner A., Zhang J. H., He M. L., Derk J., Patil S. A., Rosario
R., Lornier J., Song F., Koh H., Li H. L., Raleigh D. P., Schmidt, A. M. RAGE binds preamyloid IAPP intermediates and mediates pancreatic
beta cell proteotoxicity. J. Clin.
Invest., 2018, 128, 682-698.
Laptenok SP, Gil AA, Hall CR, Lukacs A, Iuliano JN, Jones GA, Greetham GM, Donaldson
P, Miyawaki A, Tonge PJ, Meech SR. Infrared spectroscopy reveals multistep multi-timescale
photoactivation in the photoconvertible protein archetype dronpa.
Nat. Chem. 2018; 10: 845-852.
Zheng, W.; Morales-Rivera, C. A.; Lee, J. W.; Liu, P.; Ngai, M.-Y. Catalytic C−H Trifluoromethoxylation of Arenes and Heteroarenes. Angew. Chem. Int. Ed. 2018; 57: 9645-9649.
Haj-Dahmane S, Shen RY, Elmes MW, Studholme K, Kanjiya MP, Bogdan D, Thanos PK, Miyauchi JT, Tsirka SE, Deutsch DG, Kaczocha M. Fatty-acid-binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses. Proc. Natl. Acad. Sci. U S A. 2018;115(13): 3482-3487.
Seeliger MA. More Diversity Yields a Clearer Picture into the Architecture of the Protein Kinase Domain. Cell Syst. 2018;7(4): 356-357.
Munshi MA, Gardin JM, Singh A, Luberto C, Rieger R, Bouklas T, Fries BC, Del Poeta M. The role of ceramide synthases in the pathogenesis of Cryptococcus neoformans. Cell Rep. 2018; 22(6): 1392-1400.
Bogenhagen, D.F., Ostermeyer-Fay, A., Haley, J.D., Garcia-Diaz, M. Kinetics and Mechanism of Mammalian Mitochondrial Ribosome Assembly. Cell Rep. 2018; 22(7):1935-1944.
Fernandes CM, Goldman GH, Del Poeta M. Biological Roles Played by Sphingolipids in Dimorphic and Filamentous Fungi. MBio. 2018; 9(3): e00642-18.
Lu H, Iuliano JN; Tonge PJ. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics. Curr. Opin. Chem. Biol. 2018; 44: 101-109.
Lee, K. N.; Spiegowski, D. N.; Lee, J. W.; Lim, S.; Zhao, F; Ngai, M.-Y. Transition-Metal-Free C–H Amidation and Chlorination: Synthesis of N/N′-Mono-Substituted Imidazopyridin-2ones
from N-Pyridyl-N-Hydroxylamine Intermediates. Chem. Commun.
2018; 54: 6935-6938.
Zhang, J., Li, G., Sampson, N. S. Incorporation of large cycloalkene rings into alternating copolymers allows control of glass transition and hydrophobicity. ACS Macro. Lett. 2018;7; 1068–1072.
N. Van Skike, N. K. Minkah, C.H. Hogan, G. Wu, P. T. Benziger, M. Kara, S. A. Tibetts, D. Kim-Hozapfel, J. B. French, D. G. Oldenburg, D. W. White, L. T. Krug. Viral FGARAT ORF75A promotes the specific infectivity of virus particles and gammaherpesvirus pathogenesis in mice. PLoS Pathogens, 2018; 14(2): e1006843.
T. Koga, D. A. Barkley, M. Nagao, T. Taniguchi, J.-M. Y. Carrillo, B. G. Sumpter, T. Masui, H. Kishimoto, M. Koga, J. G. Rudick, M. K. Endoh. “Interphase structures and dynamics near nanofiller surfaces in polymer solutions” Macromolecules, 2018; 51(23): 9462–9470.
Li, G., Sampson, N. S. Alternating Ring-Opening Metathesis Polymerization (AROMP) of Hydrophobic and Hydrophilic Monomers Provides Oligomers with Side-Chain Sequence Control. Macromolecules, 2018; 51: 3932–3940.
Chen X, Gaglione R, Leong T, Bednor L, de Los Santos T, Luk E, Airola M, Hollingsworth NM. Mek1 coordinates meiotic progression with DNA break repair by directly phosphorylating and inhibiting the yeast pachytene exit regulator Ndt80 PLoS Genetics, 2018;14(11): e1007832
Wu N, Fesler, Liu H, Ju J. Development of novel miR-129 mimics with enhanced efficacy to eliminate chemoresistant colon cancer stem cells. Oncotarget, 2018, 9(10): 8887-8897.
D. A. Barkley, S. U. Han, T. Koga, J. G. Rudick. “Peptide-Dendron Hybrids that Adopt Sequence-Encoded β-Sheet Conformations.” Polym. Chem. 2018; 9(40): 4994–5001.
Akter R., Bower R., Abedini A, Schmidt A. M., Hay D. L. Raleigh D. P. Amyloidogencity, Cytotoxicity, and Receptor Activity of Bovine Amylin: Implications
for Xenobiotic Transplantation and the Design of Nontoxic Amylin Variant. ACS Chem.
Biol. 2018; 13:
2747-2757.
Hossain, S.; Heckler, I.; Boon, E.M. Discovery of a nitric oxide responsive quorum sensing circuit in Vibrio cholera. ACS Chem. Biol., 2018, 13, 1964–1969.
Preston, A. N., Farr, J. D., O’Neill, B. K., Thompson, K. K., Tsirka, S. E., Laughlin, S. T. Visualizing the brain’s astrocytes with diverse chemical scaffolds. ACS Chem. Biol., 2018; 13: 1493–1498.
O’Neill, B.K.; Laughlin, S. T. Neuronal calcium recording with an engineered TEV protease. ACS Chem. Biol. 2018; 13: 1159–1164.
Paung Y, Seeliger MA. KA1 Domains: Unity in Mechanistic Diversity. Structure, 2018; 26(8): 1045-1047.
S. Yan, M. W. Elmes, S. Tong, K. Hu, M. Awwa, G. Y. H. Teng, Y. Jing, M. Freitag, Q. Gan, T. Clement, L. Wei, J. M. Sweeney, O. M. Joseph, G. S. Carbonetti, L. Wang, J. Falcone, N. Smietalo, Y. Zhou, B. Ralph, H.-C. Hsu, H. Li, R. C. Rizzo, D. G. Deutsch, M. Kaczocha, I. Ojima. SAR Studies on Truxillic Acid Mono Esters as a New Class of Antinociceptive Agents, Targeting Fatty Acid Binding Proteins. Eur. J. Med. Chem., 2018; 154: 233-252.
C. Lazzarini, K. Haranahalli, R. Rieger, H. Krishna Ananthula, P. B. Desai, A. Ashbaugh, M. J. Linke, M. T. Cushion, B. Ruzsicska, J. Haley, I. Ojima, M. Del Poeta, Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob. Agents Chemother. 2018; 62(5): e00156-18.
Bryan, A; Del Poeta M. Sphingosine-1-phosphate receptor and innate immunity. Cell. Microbiol. 2018; 20(5): e12836.
Ganapathy, U.S., Bai, L., Wei, L., Eckartt, K.A., Lett, C.M., Previti, M.L., Carrico, I.S., Seeliger, J.C. Compartment-Specific Labeling of Bacterial Periplasmic Proteins by Peroxidase-Mediated Biotinylation. ACS Infect Dis. 2018; 4: 918-925.
Stenzoski N. E., Luang, B., Holehouse A.S., Raleigh, D. P. The Unfolded State of the CTerminal Domain of L9 Expands at Low but Not at Elevated Temperatures. Biophysical J. 2018; 115: 655-663.
Suga H, Miller WT. Src signaling in a low-complexity unicellular kinome. Sci Rep. 2018; 8(1):5362.
Naidu, S. D.; Muramatsu, A.; Saito, R.; Asami, S.; Honda, T.; Hosoya, T.; Ito, K.; Yamamoto, M.; Suzuki, T.; Dinkova-Kostova, A. T. C151 in Keap1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape. Sci. Rep. 2018; 8: 8037.
Bhalla K., Jaber S., Nahid M.N., Underwood K., Beheshti A., Landon A., Bhandary B., Bastain
P., Evens A.M., Haley J., Polster B., Gartenhaus R.B. "Role of hypoxia in Diffuse Large B-cell Lymphoma:
Metabolic repression and selective translation of HK2
facilitates development of DLBCL". Sci Rep. 2018; 8(1):744-759.
T. Wang, Y. Zhang, L. Wei, Y. G. Teng, T. Honda, I. Ojima, Design, Synthesis and Biological Evaluations of Asymmetric Bow-Tie PAMAM Dendrimer-based Conjugates for Tumor-Targeted Drug Delivery. ACS Omega, 2018; 3(4): 3717–3736.
Li, Z., N. Nesbitt, L. Malone, D. Gnatenko, W. Wu, D. Wang, W. Zhu, G. Girnun, and W. Bahou. Heme degradation enzyme biliverdin IX reductase is required for stem cell glutamine metabolism. Biochem. J. 2018; 475: 1211-23.
Nesbitt, N., X. Zhang, Z. Li, J. Manso, W-Y Yen, L. Malone, J. Ripoli-Rozada, P.J.B. Pereira,
J. Wang, and W. Bahou. Identification of biliverdin IXβ reductase inhibitors with nanomolar potency using
in silico and crystallographic models. J. Biol. Chem. 2018;
293:5431-46. [journal Cover]
I. Ojima, X. Wang, Y. Jin, C. Wang, Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery. J. Nat. Prod. 2018; 81: 703-721 (2018) (ACS Editor’s Choice Article)
Nandan MO, Bialkowska AB, Yang VW. KLF5 mediates the hyper-proliferative phenotype of the intestinal epithelium in mice with intestine-specific endogenous KRas ( G12D) expression. Am J Cancer Res. 2018; 8(4): 723-731.
Guo S, Fesler A, Wang H, Ju J. microRNA based prognostic biomarkers in pancreatic cancer. Biomarker Res. 2018; 6:18.
H. Li, C. Guo, D. Kim-Holzapfel, W. Li, Y. Altshuller, B. Shroeder, W. Liu, Y. Meng, J. B. French, K. Takemaru, M. A. Frohman, S. Jia, Volumetric live-cell imaging using highresolution light-field microscopy. Biomed. Opt. Express, 2018; 10(1): 29-49.
Ganesan R, Henkels KM, Wrenshall LE, Kanaho Y, Paolo GD, Frohman MA, Gomez-Cambronero J. Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques
relies on a PLD2-CD36 functional interdependence. J. Leukoc. Biol. 2018;
103(5):867-883.
Bacon, B.; Liu, Y .; Kincaid, J.; Boon, E.M. Spectral characterization of a novel NOsensing protein in bacteria: NosP. Biochemistry, 2018; 57: 6187-6200.
J. N. Iuliano, A. A. Gil, S. P. Laptenok, C. R. Hall, J. Tolentino Collado, A. Lukacs, S. A. Hag Ahmed, J. Abyad, T. Daryaee, G. M. Greetham, I. B. Sazanovich, B. Illarionov, A. Bacher, M. Fischer, M. Towrie, J. B. French, S. R. Meech, P. J. Tonge. Variation in LOV photoreceptor activation dynamics probed by time resolved infrared spectroscopy. Biochemistry. 2018; 57(5): 620-630.
Guo J, Collins S, Miller WT, Rizzo RC. Identification of a Water-Coordinating HER2 Inhibitor by Virtual Screening Using Similarity-Based Scoring. Biochemistry, 2018; 57(32):4934-4951.
Albanese SK, Parton DL, Işık M, Rodríguez-Laureano L, Hanson SM, Behr JM, Gradia S,
Jeans C, Levinson NM, Seeliger MA, Chodera JD. An Open Library of Human Kinase Domain Constructs for Automated Bacterial
Expression. Biochemistry, 2018;57(31):
4675-4689.
Gadbery, J.; Sampson, N. S. Use of an Isotope-Coded Mass Tag (ICMT) Method to Determine the Orientation of Cholesterol Oxidase on Model Membranes. Biochemistry, 2018; 57: 5370-5378
Regenbogen E, Mo M, Romeiser J, Shroyer ALW, Escobar-Hoyos LF, Burke S, Shroyer KR. Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival. Head Neck 2018; 40:1788-1798.